



IPW
PATENT - USSN 10/741,534
Alain BARON et al.
Amylin Docket No. 0218-UTL-9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

AMYLIN PHARMACEUTICALS, INC.

Group Art Unit: 1614

Applicants: Alain BARON *et al.*

Examiner: To be assigned

Serial No.: 10/741,534

Confirmation No.: 5134

Filed: December 19, 2003

Title: *Compositions for the Treatment and Prevention of Nephropathy*

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.56, the patent documents listed on the attached Form PTO/SB/08A are being submitted herewith for consideration by the Examiner. A copy of each of the listed items is included herewith.

The references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

11 Nov 2004
Date of Deposit

Renee Zavala
Name of Person Mailing Paper
Renee Zavala
Signature of Person Mailing Paper

more than three months prior to the filing of this information disclosure statement, or prior to an action on the merits of this file.

No fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of this and any additional fees associated with this communication or credit any overpayment to Applicant's Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: 11 NOV 2004

By: James E. Butler
James E. Butler
Registration No. 40,931

AMYLIN PHARMACEUTICALS, INC.
9360 Town Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/741,534
Filing Date	December 19, 2003
First Named Inventor	Alain BARON et al.
Art Unit	1614
Examiner Name	to be assigned
Attorney Docket Number	0218-UTL-9

Sheet	1	of	1
-------	---	----	---

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.